Adamas Pharmaceuticals EBIT

The latest EBIT for ADMS is $-39M as of September 2021. That compares with $-49M in the prior-year period — up 19.4% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside Adamas Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, ADMS's EBIT moved from $-49M to $-39M — a 19.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Adamas Pharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, ADMS currently prints $-39M for EBIT, while the sector average sits near $23B. That is roughly 100.2% below the sector mean. Large gaps often invite a closer look at Adamas Pharmaceuticals's growth, margins, and balance sheet.

A EBIT figure of $-39M for ADMS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting ADMS's EBIT ($-39M), review year-over-year change from $-49M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.